TESARO Inc

Type: Company
Name: TESARO Inc
Nationality: United States
Web Address: http://tesarobio.com/
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Tesaro to Announce Third-Quarter 2014 Financial Results on November 5, 2014

WALTHAM, Mass., Oct. 22, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. ( Nasdaq:TSRO ) will announce its third-quarter 2014 financial results on Wednesday, November 5, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host ... [Published CW 50 Detroit - 23 hours ago]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Rolapitant for Preventing of Chemotherapy-Induced Nausea and Vomiting

Share this article:Rolapitant + granisetron and dexamethasone is effective in preventing chemo-induced nausea and vomiting.According to findings presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, rolapitant, ... [Published Chemotherapy Advisor - Oct 21 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

TESARO Coverage Initiated at Jefferies Group (TSRO)

Jefferies Group started coverage on shares of TESARO (NASDAQ:TSRO) in a research note released on Tuesday morning, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $40.00 target price on the stock. In other TESARO news, Director Lawrence ... [Published Mideast Time - Oct 09 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

Grab This Bargain Even Cheaper Than Director Alleva Did

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on September 29, Tesaro Inc's Director, Lawrence M..Related Stocks:SPDR S&P BIOTECH ETF TESAROStock Market XML ... [Published CEOWorld Magazine - Oct 08 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 2 reports

Jefferies Group Initiates Coverage on TESARO (TSRO)

Analysts at Jefferies Group assumed coverage on shares of TESARO (NASDAQ:TSRO)Shares of TESARO (NASDAQ:TSRO) traded down 1.21% during mid-day trading on Tuesday, hitting $26.89. 199,719 shares of the company’s stock traded hands. TESARO has a 1-year low ... [Published American Banking News - Forex - Oct 07 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Jefferies Initiates TESARO At Buy

Analysts at Jefferies initiated coverage on TESARO (NASDAQ: TSRO ) with a Buy rating.The target price for TESARO is set to $40.TESARO shares have declined 24.97% over the past 52 weeks, while the S&P 500 index has gained 18.69% in the same period.TESARO's ... [Published Benzinga.com - Oct 07 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

Business Digest for Oct. 1, 2014

Follow Daily News Business Editor Bob Tremblay on Twitter @Bob Tremblay_MW. Waltham's AMAG to buy Lumara Health for $675M AMAG Pharmaceuticals Inc., a Waltham-based specialty pharmaceutical company, this week announced that it has entered into a definitive ... [Published MetroWest Daily News - Oct 01 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 2 reports

Insider Buying: Lawrence M. Alleva Purchases 1,100 Shares of TESARO Stock (TSRO)

TESARO (NASDAQ:TSRO) Director Lawrence M. Alleva acquired 1,100 shares of TESARO stock on the open market in a transaction dated Monday, September 29th. The stock was purchased at an average cost of $26.17 per share, for a total transaction of $28,787.00. ... [Published Mideast Time - Oct 01 2014]
Entities: TESARO Inc, Insider, Stocks
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Convertible notes sale nets $170mm for Tesaro

Tesaro Inc. (cancer therapeutics) netted $170mm through the public sale of $175mm of its 3% senior notes due 2021. The notes convert to common at a rate of 28.4627 shares per $1k principal amount, or $35.13. (Tesaro's stock was averaging $29.09.)...Related ... [Published BioPortfolio - Sep 26 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Business Digest for Sept. 24, 2014

Follow Daily News Business Editor Bob Tremblay on Twitter @Bob Tremblay_MW. State's jobless rates drop in 13 areas in August The Executive Office of Labor and Workforce Development this week reported that the seasonally unadjusted unemployment rates for ... [Published Wicked Local Wayland - Sep 24 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

TESARO Prices $175 Million Notes Offering

TESARO, Inc. (Nasdaq:TSRO) announced today the pricing of $175 million aggregate principal amount of its 3.00% convertible senior notes due 2021 in an underwritten public offering. The size of the offering was increased from the previously announced aggregate ... [Published Citybizlist - Sep 24 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

305B2 - TESARO, Inc. (0001491576) (Filer)

Document Format FilesSeq Description Document Type Size 1 305B2 a14-21259_3305b2.htm 305B2 71564 2 GRAPHIC g212593bei001.gif GRAPHIC 40341 3 GRAPHIC g212593bei002.gif GRAPHIC 45453 Complete submission text file 0001104659-14-067636.txt 191135 ... [Published SEC - Sep 23 2014]
Entities: TESARO Inc

Quotes

...Londei to AnaptysBio's executive leadership team," said HamzaHamza Suria, President and Chief Executive Officer of AnaptysBio. "Dr. Londei's extensive expertise includes successful translational and clinical development of monoclonal antibodies and small molecules for dermatology, rheumatology, neurology, oncology and allergy. Novel anti-inflammatory programs are a strategic priority for AnaptysBio's proprietary pipeline, particularly our first-in-class anti-IL-33 antibody program applicable to a variety of Th2-driven diseases."
Eric Wachter, PhD and Chief Technology Officer of Provectus, said, "We are very pleased to share the patient-level PFS data at ESMO that defined our design parameters for the upcoming phase 3 trial. These study results demonstrate the potential of an intralesional approach to delay progression while alleviating symptoms of locally advanced melanoma."
"The long-term follow up data is very encouraging," said Karl Johe, PhD, Neuralstem's Chairman and Chief Scientific Officer. "In Phase I, patients 10, 11, and 12 each received 10 lumbar and five cervical injections, of 100,000 cells each, which was far below the safe maximal dose. Even so, the data shows a significant slowing of the disease progression for over three years.  If replicated on a larger scale, this could represent meaningful improvement in quality of life, and lifespan, compared to untreated patients.  In our Phase II dose escalation trial, we successfully reached the maximal dose planned, which consisted of  20 lumbar and 20 cervical injections of 400,000 cells each, more than ten times the number of stem cells delivered in the highest dose cohort of the Phase I trial."
Original Article: NEXT ARTICLE More From BioPortfolio on "AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer"

More Content

All (71) | News (46) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (17)
sort by: Date | Relevance
Could High Drug Prices Be Bad For Innovation? [Published Forbes.com - 5 hours ago]
Harvoni Approved For The Treatment Of Chronic H... [Published BioMedReports - 18 hours ago]
Tesaro to Announce Third-Quarter 2014 Financial... [Published GlobeNewswire: Acquisitions News - 22 hours ago]
Tesaro to Announce Third-Quarter 2014 Financial... [Published CW 50 Detroit - 23 hours ago]
Rolapitant for Preventing of Chemotherapy-Induc... [Published Chemotherapy Advisor - Oct 21 2014]
AnaptysBio Appoints Dr. Marco Londei to Newly C... [Published TickerTech.com - Oct 20 2014]
Most recently in 2013, 356 preclinical stage pa... [Published Live-PR.com - Oct 09 2014]
TESARO Coverage Initiated at Jefferies Group (T... [Published Mideast Time - Oct 09 2014]
Biopharma veteran Gallagher to join venture cap... [Published CNBC - Oct 09 2014]
Grab This Bargain Even Cheaper Than Director Al... [Published CEOWorld Magazine - Oct 08 2014]
Jefferies Group Initiates Coverage on TESARO (T... [Published American Banking News - Forex - Oct 07 2014]
TESARO Receives Average Recommendation of “Buy”... [Published American Banking News - Forex - Oct 07 2014]
Jefferies Initiates TESARO At Buy [Published Benzinga.com - Oct 07 2014]
Investment Analysts’ New Coverage for October, ... [Published American Banking News - Forex - Oct 07 2014]
Stock Analysts’ New Coverage for October, 2nd (... [Published American Banking News - Oct 02 2014]
Business Digest for Oct. 1, 2014 [Published MetroWest Daily News - Oct 01 2014]
Insider Buying: Lawrence M. Alleva Purchases 1,... [Published Mideast Time - Oct 01 2014]
Insider Buying: Lawrence M. Alleva Purchases 1,... [Published American Banking News - Oct 01 2014]
Medidata Appoints Mike Capone COO; PV-10 Data a... [Published BioMedReports - Sep 30 2014]
TESARO Announces Closing of $201.25 Million Pub... [Published GlobeNewswire: Acquisitions News - Sep 29 2014]
Business Digest for Sept. 26, 2014 [Published MetroWest Daily News - Sep 26 2014]
Convertible notes sale nets $170mm for Tesaro [Published BioPortfolio - Sep 26 2014]
TRACON Pharmaceuticals Expands Management Team ... [Published Town Hall - Sep 24 2014]
Business Digest for Sept. 24, 2014 [Published Wicked Local Wayland - Sep 24 2014]
TESARO Prices $175 Million Notes Offering [Published Citybizlist - Sep 24 2014]
TESARO Announces Pricing of $175 Million of 3.0... [Published GlobeNewswire: Acquisitions News - Sep 24 2014]
Airstrikes against terrorist groups send market... [Published Market Pulse Navigator - Sep 23 2014]
Tracon Pharmaceuticals racks up $27 mln Series B [Published PE Hub Blog - Sep 23 2014]
305B2 - TESARO, Inc. (0001491576) (Filer) [Published SEC - Sep 23 2014]
Neuralstem Announces ALS Long-Term Follow-Up Ph... [Published BioMedReports - Sep 23 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Tracon Pharmaceuticals racks up $27 mln Series B [Published PE Hub Blog - Sep 23 2014]
Tracon Pharmaceuticals has closed $27 million in Series B funding. The investors included New Enterprise Associates, BioMed Ventures, JAFCO Co., Nextech Invest, Brookline Investments, Arcus Ventures and BHP. MTS Health Partners and Wells Fargo ...
OPKO Licensee TESARO Submits New Drug Applicati... [Published Business Wire Health News - Sep 08 2014]
MIAMI--(BUSINESS WIRE)--Tesaro New Drug Application ...
Paradigm collaborates with TESARO on molecular ... [Published PBR - News - Aug 21 2014]
Paradigm today announced a collaboration with TESARO. ...
Paradigm Announces Molecular Profiling Collabor... [Published PR Newswire: Health - Aug 20 2014]
ANN ARBOR, Mich. and PHOENIX, Aug. 20, 2014 /PRNewswire-USNewswire/ -- Paradigm, a non-profit corporation established to bring cutting-edge next-generation sequencing and proteomic diagnostics and biomarker driven clinical trials to cancer patients, ...
Boston CEO Conference to Feature CEOs of Aegeri... [Published Business Wire Health News - May 20 2014]
BOSTON--(BUSINESS WIRE)--More than 200 leading CEOs from the biotechnology community will gather at the 2014 Boston CEO Conference June 4th and 5th at the Four Seasons Hotel in Boston. Past award winners Henri Termeer, Josh Boger, Deborah Dunsire and ...
1 2

Press Releases

sort by: Date | Relevance
Tesaro to Announce Third-Quarter 2014 Financial... [Published GlobeNewswire: Acquisitions News - 22 hours ago]
TESARO Announces Closing of $201.25 Million Pub... [Published GlobeNewswire: Acquisitions News - Sep 29 2014]
TESARO Announces Pricing of $175 Million of 3.0... [Published GlobeNewswire: Acquisitions News - Sep 24 2014]
TESARO Announces Offering of $165 Million of Co... [Published GlobeNewswire: Advertising News - Sep 22 2014]
TESARO Announces Submission of Rolapitant New D... [Published GlobeNewswire: Advertising News - Sep 08 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.